Piramal Pharma
Market cap ₹31,687 Cr
- P/E
- 58.15
- Day range
- ₹237.32 – ₹243.76
- 52-week range
- ₹132.30 – ₹253.90
- Volume
- 28.30 L
- Open
- ₹240.70
- Prev close
- ₹240.70
Latest results · Q2 FY27(consolidated)Revenue ₹2,617 Cr+28.1%Profit ₹5 CrMargin 0.2%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
PPLPHARMA in NSE indices and F&O
Research profile
Composite 48 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.7%
- ROE ÷ P/B
- -1.0%
- 12-1 mom.
- +1.2%
- Return / vol
- 0.62
- Magic Formula
- #589
- Piotroski
- 0/6
- FCF yield
- 2.4%
Appears in 7 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Piramal PharmaPPLPHARMA | ₹31,687 Cr | 58.15 | 4.00 | -4.0% | 3.0% | 13.3% | 0.72 | +28.1% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 1m agoHeadlines about Piramal Pharma from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- Price / Book
- 3.90
- ROE (FY26)
- -4.0%
- ROCE (latest year)
- 3%
- Dividend yield
- 0.00%
Moving averages (NSE)
- 20-day
- ₹228.44
- Price above
- 50-day
- ₹214.58
- Price above
- 200-day
- ₹181.7
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Public
- Promoter
- DII
- FII
- Others
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,958.57 | 2,552.36 | 1,951.14 | 2,241.75 | 2,204.22 | 2,754.07 | 1,933.71 | 2,043.72 | 2,139.87 | 2,751.77 | 2,269.92 | 2,617.06 |
| YoY Sales growth | — | — | — | — | — | — | -0.89 | -8.83 | -2.92 | -0.08 | — | — |
| Expenses | 1,690.20 | 2,022.43 | 1,746.65 | 1,900.14 | 1,866.48 | 2,193.08 | 1,827.01 | 1,885.03 | 1,944.14 | 2,291.26 | 2,074.72 | 2,268.32 |
| Operating Profit | 268.37 | 529.93 | 204.49 | 341.61 | 337.74 | 560.99 | 106.70 | 158.69 | 195.73 | 460.51 | 195.20 | 348.74 |
| OPM % | 13.7% | 20.8% | 10.5% | 15.2% | 15.3% | 20.4% | 5.5% | 7.8% | 9.2% | 16.7% | 8.6% | 13.3% |
| Other Income | 43.19 | 7.90 | 41.94 | 78.37 | 29.18 | 58.25 | 97.71 | 80.39 | 12.39 | -116.14 | 108.97 | 53.67 |
| Interest | 105.88 | 114.22 | 106.96 | 107.64 | 103.31 | 103.68 | 86.15 | 82.42 | 89.24 | 82.99 | 88.08 | 87.63 |
| Depreciation | 186.32 | 196.13 | 184.55 | 192.22 | 196.81 | 242.76 | 197.28 | 202.84 | 212.74 | 218.38 | 223.55 | 233.15 |
| Profit before tax | 19.36 | 227.48 | -45.08 | 120.12 | 66.80 | 272.80 | -79.02 | -46.18 | -93.86 | 43 | -7.46 | 81.63 |
| Tax % | 47.8% | 55.5% | 96.6% | 81.2% | 94.5% | 43.7% | 3.4% | 114.8% | 45.1% | 120.5% | 830.2% | 93.8% |
| Net Profit | 10.11 | 101.27 | -88.64 | 22.59 | 3.68 | 153.50 | -81.70 | -99.22 | -136.19 | -8.83 | -69.39 | 5.03 |
| EPS in Rs | ₹0.08 | ₹0.77 | ₹-0.67 | ₹0.17 | ₹0.03 | ₹1.16 | ₹-0.61 | ₹-0.75 | ₹-1.02 | ₹-0.07 | ₹-0.52 | ₹0.04 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-2 days since Mar 2021
+127 days since Mar 2021
+116 days since Mar 2021
+8 days since Mar 2021
0 days since Mar 2021
Strengths, risks & growth
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments (1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions [1] and various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billion [2] and Diagnostic Services was sold to Super Religare Laboratories (SRL) [3]
Strengths
None flagged by the checklist.
Risks
- Stock is trading at 4.00 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.03% over past five years.
- Company has a low return on equity of -0.88% over last 3 years.
- Company might be capitalizing the interest cost
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +7%
- 3 Years
- +8%
- TTM
- +9%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- —
- 3 Years
- -31%
- TTM
- -81%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- +28%
- 1 Year
- +25%
Return on Equity
- 10 Years
- —
- 5 Years
- 0%
- 3 Years
- -1%
- Last Year
- -4%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 34.85% | 34.85% | 34.80% | 34.80% | 0.00 pp |
| FII | 29.66% | 30.17% | 12.51% | 13.65% | +1.14 pp |
| DII | 15.68% | 15.61% | 14.57% | 14.43% | -0.14 pp |
| Public | 19.35% | 19.01% | 37.62% | 36.72% | -0.90 pp |
| Others | 0.44% | 0.34% | 0.48% | 0.40% | -0.08 pp |
Filed with NSE for Sept 2026: promoters 34.80%, public 64.80%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 12.76% (-0.48 pp)- Promoters34.9%
- Foreign institutions13.7%
- Mutual funds12.8%
- Insurance1.2%
- Other domestic institutions0.5%
- Retail9.7%
- Others27.2%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Flexi Cap Fund | 4.89% | 1.41% | +0.03 pp |
| Nippon India Pharma Fund | 0.75% | 2.61% | +0.52 pp |
| Bandhan Small Cap Fund | 0.73% | 0.67% | +0.04 pp |
| Axis Small Cap Fund | 0.47% | 0.51% | +0.51 pp |
| Franklin India Opportunities Fund | 0.46% | 1.60% | +0.31 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- Avg
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 36.0%
- Downside volatility
- 31.2%
- Worst 5% of days
- 3.8%
- Average of that tail
- 4.4%
- Max drawdown (1Y)
- 36.0%
- Below its peak
- 3.0%
Against the market
- Beta vs Nifty 50
- 1.03
- Correlation
- 0.39
- Relative strength (3M)
- +12.8%
- ATR (14)
- 3.8%
Return
- Return 1M
- +20.8%
- Return 3M
- +16.7%
- Return 6M
- +36.5%
- Return 1Y
- +22.3%
- vs 200-day average
- +31.5%
Momentum
- RSI (14)
- 62.9
- MACD histogram
- 0.29
- Stochastic %K
- 47.1
- ADX (14)
- 39.7
- +DI / −DI
- 26.2 / 10.4
- Money flow index
- 74.7
Participation
- Delivery (20d avg)
- 38.4%
- vs its 60-day baseline
- -2.4 pts
- Volume vs 20-day
- -0.4σ
- Close vs day's VWAP
- -0.9%
- 52-week position
- 93 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
0 of 6 tested
- Return on assets positive — failed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- ₹763 Cr
- FCF yield
- 2.4%
- Cash conversion
- -5.07
- Accruals ratio
- -0.110
- Net debt
- ₹5,328 Cr
- Net debt / equity
- 0.65
- EV / sales
- 3.79
- Capex intensity
- 10.0%
- Revenue CAGR
- -3.3%
- Profit CAGR
- -89.7%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividendNot available — not reported in this filing
Dividend - Re 0.14 Per Share
16 Jul 2025ex-date - dividend₹0.11
Dividend - Rs 0.11 Per Share
12 Jul 2024ex-date - rightsNot available — not reported in this filing
Rights 5:46 @ Premium Rs 71/-
2 Aug 2023ex-date
Company announcements
Please find enclosed intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ('SEBI Listing Regulations')
Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Please refer attachment.
Please refer attachment.
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 -Appointment of Senior Management Personnel.
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Changes in Senior Management Personnel.
The Exchange has sought Clarification from Piramal Pharma Ltd with reference to the media report appearing on https://www.thehindubusinessline.com/ dated September 30, 2026 (Link: https://www.thehindubusinessline.com/brandhub/pr-release/ontario-contributes-17-million-investment-to-advance-life-sciences-innovation-at-piramal-pharmas-aurora-facility/article71526588.ece) ....
Please refer the attachment.
Please refer attachment.
Please refer attached file
Please refer attached file
Please refer attached file
Please refer attached file
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG
Please refer attached file
Filed with BSE (scrip 543635); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Buybacks, open offers & rights issues
- Rights issue - Letter of Offer
Piramal Pharma Limited - Letter of Offer
28 Jul 2023Read on SEBI - Rights issue - DLOF
Piramal Pharma Limited - DLOF
31 Mar 2023Read on SEBI
Regulatory orders
- Order
Order under section 15-I of SEBI Act 1992 in the matter of Piramal Pharma Limited
8 Nov 2024Read on SEBI - Adjudication order
Adjudication Order in respect of Piramal Pharma Ltd. in the matter of Piramal Enterprises Ltd.
31 Aug 2023Read on SEBI
Documents
Earnings calls
- Oct 2026SlidesRecording
- Jul 2026TranscriptSlidesRecording
- Apr 2026TranscriptSlidesRecording
- Jan 2026TranscriptSlides
- Nov 2025TranscriptSlides
- Oct 2025Transcript
Credit ratings
- Rating update · 17 Jul from care
- Rating update · 15 Oct 2025 from icra
- Rating update · 18 Jul 2025 from care
- Rating update · 6 Mar 2025 from care
- Rating update · 22 Oct 2024 from icra
- Rating update · 4 Jul 2024 from care
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 28 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Piramal Pharma: common questions
Answered from the figures on this page.